Vistagen Therapeutics VTGN Institutional Ownership

Ownership Summary

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) has 56 institutional investors with active 13F positions as of March 2026.

• Their combined ownership stood at 38.7% of outstanding shares in March 2026, up from 34.2% in December 2025.
• They increased total shares held in VTGN by 25.04% quarter over quarter, and investors in Vistagen Therapeutics increased 12.0% from a year ago.
• Of these 56 funds, 29 grew their exposure to Vistagen Therapeutics, 10 cut back, and 17 maintained positions.
• Combined, these investors held 14.73Mn shares in VTGN for March 2026, up by 2.95Mn shares quarter on quarter, and down 1.24Mn shares year over year.
• ORBIMED ADVISORS LLC leads ownership in VTGN with 3.06Mn shares as of March 31, 2026, equal to 8.04% of outstanding shares.
• Leading buyers of Vistagen Therapeutics shares for the quarter ending March 2026 were VANGUARD CAPITAL MANAGEMENT LLC (1.57Mn), ACADIAN ASSET MANAGEMENT LLC (589.66K), TWO SIGMA INVESTMENTS, LP (274.05K), MILLENNIUM MANAGEMENT LLC (233.36K), VANGUARD FIDUCIARY TRUST CO (217.7K).
• Leading sellers of Vistagen Therapeutics shares for the quarter ending March 2026 were ADAR1 Capital Management, LLC (496.01K), JANE STREET GROUP, LLC (254.32K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (192.18K), GROUP ONE TRADING LLC (86.26K), Morgan Stanley (12.66K).
• According to Business Quant data, leading holders of VTGN for March 2026 are ORBIMED ADVISORS LLC (3.06Mn), TCG Crossover Management, LLC (2.68Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.57Mn), ADAR1 Capital Management, LLC (751.14K), STEMPOINT CAPITAL LP (616.75K), ACADIAN ASSET MANAGEMENT LLC (589.66K), Ikarian Capital, LLC (519.08K), TWO SIGMA INVESTMENTS, LP (469.62K), GEODE CAPITAL MANAGEMENT, LLC (453.39K), BlackRock, Inc. (448.51K).